Compounds > 2,2-bis(4-glycidyloxyphenyl)propane
Page last updated: 2024-10-23

2,2-bis(4-glycidyloxyphenyl)propane and Carcinoma, Renal Cell

2,2-bis(4-glycidyloxyphenyl)propane has been researched along with Carcinoma, Renal Cell in 1 studies

2,2-bis(4-glycidyloxyphenyl)propane: structure

Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mahmoud, MF1
El Shazly, SM1

Other Studies

1 other study available for 2,2-bis(4-glycidyloxyphenyl)propane and Carcinoma, Renal Cell

ArticleYear
Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2013, Volume: 51

    Topics: Animals; Benzhydryl Compounds; Carcinoma, Renal Cell; Cell Line, Tumor; Cisplatin; Epoxy Compounds;

2013